新たに診断された転移性ユーイング肉腫患者の治療におけるガニツマブ併用または併用化学療法
新たに転移性ユーイング肉腫と診断された患者に対する多剤併用化学療法へのIGF-1Rモノクローナル抗体ガニツマブ(AMG 479、NSC# 750008)の追加を評価する無作為化第3相試験
This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Treatment with drugs that block the IGF-1R pathway, such as ganitumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether adding ganitumab to combination chemotherapy is more effective in treating patients with newly diagnosed metastatic Ewing sarcoma.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
PRIMARY OBJECTIVES:
I. To determine if event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of ganitumab (AMG 479).
SECONDARY OBJECTIVES:
I. To describe the toxicity of the addition of ganitumab to multimodality therapy for patients with newly diagnosed metastatic Ewing sarcoma.
II. To compare overall survival in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab.
EXPLORATORY OBJECTIVES:
I. To compare bone marrow response rates in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab.
II. To describe the toxicity of 6 months of ganitumab monotherapy as maintenance therapy following multimodality therapy in patients with newly diagnosed metastatic Ewing sarcoma.
III. To describe trough levels of ganitumab in a cohort of patients with Ewing sarcoma < 21 years of age treated with 18 mg/kg.
IV. To describe the feasibility of and local failure rates following hypofractionated stereotactic body radiotherapy (SBRT) directed at bone metastases in patients with newly diagnosed metastatic Ewing sarcoma.
V. To determine if EFS, overall survival, bone marrow response rates, and toxicity differ based on serum markers of the insulin-like growth factor 1 (IGF-1) pathway in patients with newly diagnosed metastatic Ewing sarcoma treated with interval compressed chemotherapy with and without the addition of ganitumab.
VI. To determine if EFS, overall survival, and bone marrow response rates differ based on protein, deoxyribose nucleic acid (DNA), and ribonucleic acid (RNA) marker in patients with newly diagnosed metastatic Ewing sarcoma treated with interval compressed chemotherapy with and without the addition of ganitumab.
VII. To evaluate bone marrow micrometastatic disease and tumor cell surface IGF-1R expression at diagnosis and after 3 and 6 cycles of study therapy in patients with newly diagnosed metastatic Ewing sarcoma.
VIII. To determine if the presence of germline polymorphisms in EGFR correlate with response to multiagent therapy with and without ganitumab.
IX. To investigate the ability of fludeoxyglucose F 18-positron emission tomography (FDG-PET) to augment conventional response assessment of primary Ewing sarcoma tumors by magnetic resonance imaging (MRI).
X. To explore FDG-PET response at the primary tumor as a prognostic marker and as a predictive biomarker of clinical activity of IGF-1R inhibition in patients with newly diagnosed metastatic Ewing sarcoma.
XI. To collect data on institutional testing for Ewing sarcoma breakpoint region 1 (EWSR1) translocation status in patients enrolling on study.
XII. To explore the capacity of plasma cell-free DNA analysis to detect tumor-specific genetic changes at initial diagnosis and after initiation of protocol therapy.
XIII. To collect a population of bone marrow metastatic tumor cells by flow cytometry for genomic profiling.
OUTLINE: Patients are randomized to 1 of 2 treatment regimens. (As of 3/20/2019, the study is closed to accrual and patients in Regimen B no longer receive ganitumab.)
REGIMEN A (vincristine sulfate, doxorubicin hydrochloride and cyclophosphamide [VDC] and ifosfamide and etoposide phosphate [IE]):
INDUCTION THERAPY: Patients receive vincristine sulfate intravenously (IV) over 1 minute on day 1, doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2, and cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 5, and 9, and ifosfamide IV over 1 hour on days 1 to 5 and etoposide phosphate IV over 1-2 hours on days 1 to 5 of weeks 3, 7, and 11.
LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.
CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1, 7, 9, and 13; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 1 and 7, cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 7, 9, and 13, ifosfamide IV over 1 hour on days 1 to 5 of weeks 3, 5, 11, and 15, and etoposide phosphate IV over 1-2 hours on days 1 to 5 of weeks 3, 5, 11, and 15.
METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or external beam radiation therapy (EBRT).
REGIMEN B (VDC/IE + ganitumab):
INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.
LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.
CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15.
METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT.
MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles.
After completion of study treatment, patients are followed for 10 years.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- Children's Hospital of Alabama
-
Mobile、Alabama、アメリカ、36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa、Arizona、アメリカ、85202
- Banner Children's at Desert
-
Phoenix、Arizona、アメリカ、85016
- Phoenix Childrens Hospital
-
Tucson、Arizona、アメリカ、85719
- Banner University Medical Center - Tucson
-
Yuma、Arizona、アメリカ、85364
- Onvida Health Yuma Medical Center
-
-
Arkansas
-
Hot Springs、Arkansas、アメリカ、71913
- CHI Saint Vincent Cancer Center Hot Springs
-
Little Rock、Arkansas、アメリカ、72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey、California、アメリカ、90242
- Kaiser Permanente Downey Medical Center
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda、California、アメリカ、92354
- Loma Linda University Medical Center
-
Long Beach、California、アメリカ、90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles、California、アメリカ、90027
- Children's Hospital Los Angeles
-
Madera、California、アメリカ、93636
- Valley Children's Hospital
-
Oakland、California、アメリカ、94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland、California、アメリカ、94611
- Kaiser Permanente-Oakland
-
Orange、California、アメリカ、92868
- Children's Hospital of Orange County
-
Palo Alto、California、アメリカ、94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento、California、アメリカ、95816
- Sutter Medical Center Sacramento
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
San Diego、California、アメリカ、92123
- Rady Children's Hospital - San Diego
-
San Francisco、California、アメリカ、94158
- UCSF Medical Center-Mission Bay
-
San Francisco、California、アメリカ、94143
- UCSF Medical Center-Parnassus
-
Torrance、California、アメリカ、90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Children's Hospital Colorado
-
Colorado Springs、Colorado、アメリカ、80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs、Colorado、アメリカ、80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver、Colorado、アメリカ、80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Denver、Colorado、アメリカ、80210
- AdventHealth Porter
-
Durango、Colorado、アメリカ、81301
- Mercy Medical Center
-
Durango、Colorado、アメリカ、81301
- CommonSpirit Cancer Center Mercy
-
Golden、Colorado、アメリカ、80401
- Mountain Blue Cancer Care Center
-
Lakewood、Colorado、アメリカ、80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood、Colorado、アメリカ、80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton、Colorado、アメリカ、80122
- AdventHealth Littleton
-
Longmont、Colorado、アメリカ、80501
- Longmont United Hospital
-
Longmont、Colorado、アメリカ、80501
- Rocky Mountain Cancer Centers-Longmont
-
Parker、Colorado、アメリカ、80138
- Rocky Mountain Cancer Centers-Parker
-
Parker、Colorado、アメリカ、80138
- AdventHealth Parker
-
Pueblo、Colorado、アメリカ、81004
- Saint Mary Corwin Medical Center
-
Pueblo、Colorado、アメリカ、81008
- Rocky Mountain Cancer Centers - Pueblo
-
Thornton、Colorado、アメリカ、80260
- Rocky Mountain Cancer Centers-Thornton
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- Connecticut Children's Medical Center
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children's National Medical Center
-
Washington D.C.、District of Columbia、アメリカ、20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Myers、Florida、アメリカ、33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville、Florida、アメリカ、32610
- UF Health Cancer Institute - Gainesville
-
Hollywood、Florida、アメリカ、33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville、Florida、アメリカ、32207
- Nemours Children's Clinic-Jacksonville
-
Miami、Florida、アメリカ、33155
- Nicklaus Children's Hospital
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando、Florida、アメリカ、32827
- Nemours Children's Hospital
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
Orlando、Florida、アメリカ、32806
- Arnold Palmer Hospital for Children
-
Pensacola、Florida、アメリカ、32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg、Florida、アメリカ、33701
- Johns Hopkins All Children's Hospital
-
Tampa、Florida、アメリカ、33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach、Florida、アメリカ、33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta、Georgia、アメリカ、30912
- Augusta University Medical Center
-
Savannah、Georgia、アメリカ、31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Straub Clinic and Hospital
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
Honolulu、Hawaii、アメリカ、96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Aurora、Illinois、アメリカ、60504
- Rush-Copley Medical Center
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60611
- Lurie Children's Hospital-Chicago
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood、Illinois、アメリカ、60153
- Loyola University Medical Center
-
Mount Vernon、Illinois、アメリカ、62864
- SSM Health Good Samaritan
-
Oak Lawn、Illinois、アメリカ、60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge、Illinois、アメリカ、60068
- Advocate Children's Hospital-Park Ridge
-
Peoria、Illinois、アメリカ、61637
- OSF Children's Hospital of Illinois
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Saint John's Hospital
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Urbana、Illinois、アメリカ、61801
- The Carle Foundation Hospital
-
Yorkville、Illinois、アメリカ、60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Evansville、Indiana、アメリカ、47713
- Deaconess Clinic Downtown
-
Indianapolis、Indiana、アメリカ、46202
- Riley Hospital for Children
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Saint Vincent Indianapolis Hospital
-
Michigan City、Indiana、アメリカ、46360
- Franciscan Saint Anthony Health-Michigan City
-
Michigan City、Indiana、アメリカ、46360
- Woodland Cancer Care Center
-
Newburgh、Indiana、アメリカ、47630
- Chancellor Center for Oncology
-
-
Iowa
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs、Iowa、アメリカ、51503
- Alegent Health Mercy Hospital
-
Creston、Iowa、アメリカ、50801
- Greater Regional Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50309
- Blank Children's Hospital
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Bardstown、Kentucky、アメリカ、40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin、Kentucky、アメリカ、40701
- Commonwealth Cancer Center-Corbin
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
Lexington、Kentucky、アメリカ、40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington、Kentucky、アメリカ、40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
London、Kentucky、アメリカ、40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville、Kentucky、アメリカ、40202
- Jewish Hospital
-
Louisville、Kentucky、アメリカ、40202
- Norton Children's Hospital
-
Louisville、Kentucky、アメリカ、40245
- UofL Health Medical Center Northeast
-
Louisville、Kentucky、アメリカ、40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville、Kentucky、アメリカ、40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
New Orleans、Louisiana、アメリカ、70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor、Maine、アメリカ、04401
- Eastern Maine Medical Center
-
Scarborough、Maine、アメリカ、04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、アメリカ、21215
- Sinai Hospital of Baltimore
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda、Maryland、アメリカ、20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital Cancer Center
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
Worcester、Massachusetts、アメリカ、01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- C S Mott Children's Hospital
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Rogel Cancer Center
-
Battle Creek、Michigan、アメリカ、49017
- Bronson Battle Creek
-
Detroit、Michigan、アメリカ、48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit、Michigan、アメリカ、48236
- Henry Ford Health Saint John Hospital
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Grand Rapids、Michigan、アメリカ、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、アメリカ、49048
- Beacon Kalamazoo
-
Muskegon、Michigan、アメリカ、49444
- Trinity Health Muskegon Hospital
-
Niles、Michigan、アメリカ、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Port Huron、Michigan、アメリカ、48060
- Lake Huron Medical Center
-
Port Huron、Michigan、アメリカ、48060
- Huron Medical Center PC
-
Reed City、Michigan、アメリカ、49677
- Corewell Health Reed City Hospital
-
Royal Oak、Michigan、アメリカ、48073
- Corewell Health Children's
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
-
Minnesota
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Cancer Center
-
Minneapolis、Minnesota、アメリカ、55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota/Masonic Cancer Center
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
-
Missouri
-
Bolivar、Missouri、アメリカ、65613
- Central Care Cancer Center - Bolivar
-
Branson、Missouri、アメリカ、65616
- Cox Cancer Center Branson
-
Columbia、Missouri、アメリカ、65212
- University of Missouri Children's Hospital
-
Joplin、Missouri、アメリカ、64804
- Freeman Health System
-
Joplin、Missouri、アメリカ、64804
- Mercy Hospital Joplin
-
Kansas City、Missouri、アメリカ、64108
- Children's Mercy Hospitals and Clinics
-
Rolla、Missouri、アメリカ、65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla、Missouri、アメリカ、65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph、Missouri、アメリカ、64506
- Heartland Regional Medical Center
-
Springfield、Missouri、アメリカ、65807
- CoxHealth South Hospital
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63109
- Mercy Infusion Center - Chippewa
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、アメリカ、63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Bellevue、Nebraska、アメリカ、68123
- Nebraska Medicine-Bellevue
-
Grand Island、Nebraska、アメリカ、68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney、Nebraska、アメリカ、68847
- CHI Health Good Samaritan
-
Kearney、Nebraska、アメリカ、68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln、Nebraska、アメリカ、68510
- Saint Elizabeth Regional Medical Center
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center
-
Omaha、Nebraska、アメリカ、68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha、Nebraska、アメリカ、68118
- Nebraska Medicine-Village Pointe
-
Omaha、Nebraska、アメリカ、68122
- Alegent Health Immanuel Medical Center
-
Omaha、Nebraska、アメリカ、68130
- Alegent Health Lakeside Hospital
-
Omaha、Nebraska、アメリカ、68114
- Children's Hospital and Medical Center of Omaha
-
Omaha、Nebraska、アメリカ、68122
- Hematology and Oncology Consultants PC
-
Papillion、Nebraska、アメリカ、68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City、Nevada、アメリカ、89703
- Carson Tahoe Regional Medical Center
-
Henderson、Nevada、アメリカ、89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Las Vegas、Nevada、アメリカ、89144
- Summerlin Hospital Medical Center
-
Las Vegas、Nevada、アメリカ、89109
- Sunrise Hospital and Medical Center
-
Las Vegas、Nevada、アメリカ、89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas、Nevada、アメリカ、89102
- University Medical Center of Southern Nevada
-
Las Vegas、Nevada、アメリカ、89128
- Ann M Wierman MD LTD
-
Pahrump、Nevada、アメリカ、89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno、Nevada、アメリカ、89502
- Renown Regional Medical Center
-
Reno、Nevada、アメリカ、89503
- Saint Mary's Regional Medical Center
-
Reno、Nevada、アメリカ、89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
New Brunswick、New Jersey、アメリカ、08901
- Saint Peter's University Hospital
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark、New Jersey、アメリカ、07112
- Newark Beth Israel Medical Center
-
Paterson、New Jersey、アメリカ、07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany、New York、アメリカ、12208
- Albany Medical Center
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Glens Falls、New York、アメリカ、12801
- Glens Falls Hospital
-
Mineola、New York、アメリカ、11501
- NYU Langone Hospital - Long Island
-
New Hyde Park、New York、アメリカ、11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York、New York、アメリカ、10029
- Mount Sinai Hospital
-
New York、New York、アメリカ、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester、New York、アメリカ、14642
- University of Rochester
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx、New York、アメリカ、10467
- Children's Hospital at Montefiore
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center - Moses Campus
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center-Weiler Hospital
-
Valhalla、New York、アメリカ、10595
- New York Medical College
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28801
- Mission Hospital
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte、North Carolina、アメリカ、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44308
- Children's Hospital Medical Center of Akron
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati、Ohio、アメリカ、45242
- Bethesda North Hospital
-
Cincinnati、Ohio、アメリカ、45247
- TriHealth Cancer Institute-Westside
-
Cincinnati、Ohio、アメリカ、45255
- TriHealth Cancer Institute-Anderson
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44106
- Rainbow Babies and Childrens Hospital
-
Columbus、Ohio、アメリカ、43205
- Nationwide Children's Hospital
-
Dayton、Ohio、アメリカ、45404
- Dayton Children's Hospital
-
Toledo、Ohio、アメリカ、43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health and Science University
-
Portland、Oregon、アメリカ、97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem、Pennsylvania、アメリカ、18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville、Pennsylvania、アメリカ、17822
- Geisinger Medical Center
-
Hershey、Pennsylvania、アメリカ、17033
- Penn State Children's Hospital
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
Philadelphia、Pennsylvania、アメリカ、19134
- Saint Christopher's Hospital for Children
-
Philadelphia、Pennsylvania、アメリカ、19102
- Drexel University School of Medicine
-
Pittsburgh、Pennsylvania、アメリカ、15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Columbia、South Carolina、アメリカ、29203
- Prisma Health Richland Hospital
-
Greenville、South Carolina、アメリカ、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
Greenville、South Carolina、アメリカ、29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37403
- T C Thompson Children's Hospital
-
Chattanooga、Tennessee、アメリカ、37404
- Memorial Hospital
-
Hixson、Tennessee、アメリカ、37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Knoxville、Tennessee、アメリカ、37916
- East Tennessee Childrens Hospital
-
Memphis、Tennessee、アメリカ、38105
- Saint Jude Children's Research Hospital
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville、Tennessee、アメリカ、37203
- The Children's Hospital at TriStar Centennial
-
Ooltewah、Tennessee、アメリカ、37363
- Memorial GYN Plus
-
-
Texas
-
Austin、Texas、アメリカ、78723
- Dell Children's Medical Center of Central Texas
-
Bryan、Texas、アメリカ、77802
- Saint Joseph Regional Cancer Center
-
Corpus Christi、Texas、アメリカ、78411
- Driscoll Children's Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、アメリカ、75230
- Medical City Dallas Hospital
-
El Paso、Texas、アメリカ、79905
- El Paso Children's Hospital
-
Fort Worth、Texas、アメリカ、76104
- Cook Children's Medical Center
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock、Texas、アメリカ、79410
- Covenant Children's Hospital
-
Lubbock、Texas、アメリカ、79415
- UMC Cancer Center / UMC Health System
-
Lubbock、Texas、アメリカ、79430
- Texas Tech University Health Sciences Center-Lubbock
-
San Antonio、Texas、アメリカ、78229
- University of Texas Health Science Center at San Antonio
-
San Antonio、Texas、アメリカ、78207
- Children's Hospital of San Antonio
-
San Antonio、Texas、アメリカ、78229
- Methodist Children's Hospital of South Texas
-
Temple、Texas、アメリカ、76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113
- Primary Children's Hospital
-
-
Vermont
-
Berlin Corners、Vermont、アメリカ、05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington、Vermont、アメリカ、05401
- University of Vermont Medical Center
-
Burlington、Vermont、アメリカ、05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042
- Inova Fairfax Hospital
-
Norfolk、Virginia、アメリカ、23507
- Children's Hospital of The King's Daughters
-
Portsmouth、Virginia、アメリカ、23708-2197
- Naval Medical Center - Portsmouth
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke、Virginia、アメリカ、24014
- Carilion Children's
-
-
Washington
-
Burien、Washington、アメリカ、98166
- Saint Anne Hospital
-
Enumclaw、Washington、アメリカ、98022
- Saint Elizabeth Hospital
-
Federal Way、Washington、アメリカ、98003
- Saint Francis Hospital
-
Lakewood、Washington、アメリカ、98499
- Saint Clare Hospital
-
Poulsbo、Washington、アメリカ、98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
Silverdale、Washington、アメリカ、98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane、Washington、アメリカ、99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma、Washington、アメリカ、98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma、Washington、アメリカ、98405
- Northwest Medical Specialties PLLC
-
Tacoma、Washington、アメリカ、98431
- Madigan Army Medical Center
-
Tacoma、Washington、アメリカ、98405
- Franciscan Research Center-Northwest Medical Plaza
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Marinette、Wisconsin、アメリカ、54143
- Saint Vincent Hospital Cancer Center at Marinette
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、アメリカ、53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Québec、カナダ、G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary、Alberta、カナダ、T3B 6A8
- Alberta Children's Hospital
-
Edmonton、Alberta、カナダ、T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、カナダ、A1B 3V6
- Janeway Child Health Centre
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston、Ontario、カナダ、K7L 2V7
- Kingston Health Sciences Centre
-
London、Ontario、カナダ、N6A 5W9
- Children's Hospital
-
Ottawa、Ontario、カナダ、K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal、Quebec、カナダ、H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal、Quebec、カナダ、H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
-
-
-
-
San Juan、プエルトリコ、00926
- University Pediatric Hospital
-
San Juan、プエルトリコ、00912
- San Jorge Children's Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other metastatic site
-
For the purpose of this study metastatic disease is defined as one or more of the following:
-
Lesions which are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a bone or body cavity with the primary tumor; skip lesions in the same bone as the primary tumor do not constitute metastatic disease; skip lesions in an adjacent bone are considered bone metastases; if there is any doubt whether lesions are metastatic, a biopsy of those lesions should be performed
-
Contralateral pleural effusion and/or contralateral pleural nodules
-
Distant lymph node involvement
-
Patients with pulmonary nodules are considered to have metastatic disease if the patient has:
- Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is biopsied and negative for tumor
- Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not considered to have lung metastasis unless biopsy documents tumor
-
Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma based on hematoxylin and eosin (H&E) stains; in the absence of morphologic evidence of marrow involvement on H&E, patients with bone marrow involvement detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or immunohistochemistry will NOT be considered to have clinical bone marrow involvement for the purposes of this study
- This study requires bilateral bone marrow biopsies at study entry; the suggested approach for patients with large pelvic tumors in which a posterior iliac crest bone marrow biopsy would track through the tumor is to instead undergo 2 marrow biopsies on the contralateral side (either 2 posterior biopsies or one posterior and one anterior biopsy)
-
Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans require confirmatory anatomic imaging with either MRI or computed tomography (CT) (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole body technetium bone scans may be performed at the discretion of the investigator and are not required; for patients without other sites of metastatic disease whose sole metastatic site to qualify for study entry is a single area suspicious for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic imaging evidence of an associated soft tissue mass at that site is required for study entry
-
-
Patients must have adequate tumor tissue to meet the minimum requirement for submission
-
Enrolling institutions are reminded that submission of pre-treatment serum, tumor tissue and whole blood is required
-
Patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if excision was attempted or accomplished as long as adequate anatomic imaging (MRI for most primary tumor sites) was obtained prior to surgery
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (performed within 7 days prior to enrollment):
- Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females
- Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and females
- Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females
- Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females
- Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females
- Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females
- Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for females
- Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for females
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment), and
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment) (except for patients with liver metastasis who may enroll if ALT < 5 times ULN for age)
-
Shortening fraction of >= 27% or
-
Ejection fraction of >= 50%
-
Patients must have a normal blood sugar level for age to participate; if an initial random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to repeat this test as a fasting draw
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with regional node involvement as their only site of disease beyond the primary tumor will not be eligible
- Patients whose primary tumors arise in the intra-dural soft tissue (e.g. brain and spinal cord) are not eligible
- Patients who have received prior chemotherapy or radiation therapy are not eligible
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; lactating females are not eligible unless they have agreed not to breastfeed their infants for the duration of protocol therapy; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy
- Patients with known pre-existing diabetes mellitus will be excluded from study
- Patients receiving chronic pharmacologic doses of corticosteroids are not eligible; for the purposes of eligibility, chronic exposure is defined as anticipated exposure of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned exposure) must still meet the normal blood glucose requirement; patients receiving chronic inhaled corticosteroids or chronic physiologic replacement doses of corticosteroids are eligible
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Regimen A (VDC/IE)
See Design Details. |
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo EBRT
他の名前:
Given IV
他の名前:
Undergo SBRT
他の名前:
Undergo surgery |
|
実験的:Regimen B (VDC/IE + ganitumab)
INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11. LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy. CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15. METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT. MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles. |
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo EBRT
他の名前:
Given IV
他の名前:
Undergo SBRT
他の名前:
Undergo surgery Given IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event-free Survival
時間枠:5 years after enrollment
|
Estimated 5-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. |
5 years after enrollment
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival
時間枠:5 years after enrollment
|
Time from study enrollment to death or last patient contact. |
5 years after enrollment
|
|
Frequency of Toxicity-events
時間枠:Up to 202 days
|
The number of induction or consolidation reporting periods in which a CTC version 4 codeable grade 4 or greater non-hematological adverse event, grade 3 or greater left ventricular systolic dysfunction or the reporting period is terminated because of a CTC codeable event. |
Up to 202 days
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Serum IGF Pathway Component and Tissue Protein, Deoxyribonucleic Acid (DNA), and Ribonucleic Acid Markers
時間枠:Up to 10 years
|
In addition to the log rank test the modeling approach will be used for the primary study comparison. Linear trend in EFS-risk will be investigated by segregating the marker level according to quartiles. For bone marrow response rate analyses, Fisher's exact test will be used to compare the objective bone marrow response rate (complete response vs. incomplete response) at start of local control between patients with biomarker levels above and below the group median. |
Up to 10 years
|
|
Tumor Cell Surface IGF-1R Expression
時間枠:Up to 307 days
|
Extent of tumor cell IGF-1R co-expression will also be reported. Change in tumor cell IGF-1R co-expression in patients treated with and without ganitumab will be reported descriptively. |
Up to 307 days
|
|
Germline Polymorphisms in EGFR
時間枠:Up to 10 years
|
EFS will be compared between patients with and without the presence of the minor allele using the log rank test, both for the entire patient population and for patients randomized to ganitumab. |
Up to 10 years
|
|
EWS Translocation
時間枠:Up to 10 years
|
The institutional result of EWS tumor testing will be categorized as translocation detected (yes v. no) and the type of translocation detected will also be recorded. The proportion of patients with a particular EWS translocation variant will be tabulated. |
Up to 10 years
|
|
Circulating Tumor DNA (ctDNA) Testing
時間枠:Up to 202 days
|
Will report the proportion of patients that have a change in translocation result associated with ctDNA testing across time periods. |
Up to 202 days
|
|
Serial Genomic Profiling
時間枠:Up to 307 days
|
Will be identified by flow cytometry. Profiles will be presented graphically, and samples obtained from different sites of tumor within the same individual will also be presented. |
Up to 307 days
|
|
Occurrence of Sinusoidal Obstructive Disease (SOS) Associated With the Addition of Ganitumab to VDC/IE
時間枠:Up to 202 days
|
The number of induction and maintenance cycles received by patients randomized to the experimental therapy where SOS is observed. Only patients who receive all reporting period therapy or experience SOS will contribute to this outcome measure. |
Up to 202 days
|
|
Frequency of Resolution of Bone Marrow Metastases
時間枠:Up to 84 days
|
The number of patients who are enrolled with bone marrow metastases whose bone marrow disease is not detected after evaluation at the time of of first local control measure or the end of the Induction reporting period, whichever comes first. Only eligible patients who receive at least one dose of randomized treatment assignment will be considered for this measure. |
Up to 84 days
|
|
Frequency of Toxicity Events During Ganitumab Maintenance
時間枠:Up to 307 days
|
The number of induction or consolidation reporting periods in which a CTC version 4 codeable non-hematological adverse event, grade 3 left ventricular systolic dysfunction or the reporting period is terminated because of a CTC codeable event. |
Up to 307 days
|
|
Trough Levels of Serum Ganitumab
時間枠:Up to 15 days
|
Trough levels of serum ganitumab prior to the second dose of ganitumab during induction obtained will be categorized as less than 10 micrograms per milliliter or greater than or equal to 10 micrograms per milliliter. This analysis will be conducted for the first 10 eligible patients who receive ganitumab. |
Up to 15 days
|
|
Proportion of Patients Who Successfully Receive Planned Stereotactic Body Radiotherapy (SBRT)
時間枠:202 days
|
A patient who has SBRT planned for at least one metastatic site and receives successful SBRT treatment to at least 85% of metastatic sites in the treatment plan. Successful treatment is determined by IROC review criteria. Only eligible patients start the metastatic site radiation reporting period will be considered for this outcome measure. |
202 days
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Steven G DuBois、Children's Oncology Group
出版物と役立つリンク
一般刊行物
- DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, Chen HX, Seibel NL, Boron M, Terezakis S, Hill-Kayser C, Hayes A, Reid JM, Teot L, Rakheja D, Womer R, Arndt C, Lessnick SL, Crompton BD, Kolb EA, Daldrup-Link H, Eutsler E, Reed DR, Janeway KA, Gorlick RG. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 Apr 10;41(11):2098-2107. doi: 10.1200/JCO.22.01815. Epub 2023 Jan 20.
- von Kruchten R, DelRocco NJ, Adams LC, Singh SB, Varniab ZS, Bender JG, Krailo MD, DuBois S, Daldrup-Link HE. Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial. Magn Reson Imaging. 2026 Oct;132:110706. doi: 10.1016/j.mri.2026.110706. Epub 2026 May 27.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 組織型別の新生物
- 肉腫
- 新生物、結合組織および軟部組織
- 骨肉腫
- 新生物、骨組織
- 新生物、結合組織
- 肉腫、ユーイング
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 調査手法
- 治療
- 外科的処置、手術
- 炭化水素
- 炭化水素、周期的
- 炭水化物
- 物理現象
- アルカロイド
- ポドフィロトキシン
- テトラヒドロノフタレン
- ナフタレン
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グルコシド
- グリコシド
- インドール
- 組織
- ヘルスケアの経済学と組織
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- ヴィンカアルカロイド
- セコロガニントリプタミンアルカロイド
- インドールアルカロイド
- インドリジジン
- インドリジン
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- 放射線療法
- 定位技術
- 脳神経外科手術
- ダウノルビシン
- オキサジン
- シクロホスファミド
- エトポシド
- ドキソルビシン
- ビンクリスチン
- イホスファミド
- 放射線
- トピックとしての議会
- 放射線手術
- エトポシドリン酸
- ガニツマブ
その他の研究ID番号
その他の研究ID番号
- NCI-2014-02380
- U10CA180886 (米国 NIH グラント/契約)
- U10CA098543 (米国 NIH グラント/契約)
- NCI-2014-02380 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- AEWS1221 (その他の識別子:CTEP)
- s15-00442
- AEWS1221
- AEWS1221 (その他の識別子:Children's Oncology Group)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。